3.41
+0.06(+1.79%)
Currency In USD
| Previous Close | 3.35 |
| Open | 3.38 |
| Day High | 3.54 |
| Day Low | 3.37 |
| 52-Week High | 4.6 |
| 52-Week Low | 2.75 |
| Volume | 183,559 |
| Average Volume | 288,103 |
| Market Cap | 288.02M |
| PE | -1.65 |
| EPS | -2.07 |
| Moving Average 50 Days | 3.27 |
| Moving Average 200 Days | 3.58 |
| Change | 0.06 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $112.39 as of January 02, 2025 at a share price of $3.41. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $371.06 as of January 02, 2025 at a share price of $3.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
GlobeNewswire Inc.
Dec 16, 2024 10:00 AM GMT
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
GlobeNewswire Inc.
Dec 04, 2024 12:00 PM GMT
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration Regimen Was Generally Safe and Well-Tolerated Global Phase 3 Program Initiation Expected Early in 2025 BOST
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
GlobeNewswire Inc.
Nov 26, 2024 12:00 PM GMT
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today annou